CYRUS QUEROL: Open Payments
NPI 1013365923 · POMONA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$690 in 30 payments from 9 companies in 2025. Trend: 2023 $646 · 2024 $574 · 2025 $690
Food & beverage: $690
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 9 | $184 |
| Regeneron Healthcare Solutions, Inc. | 4 | $111 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 5 | $97 |
| Galderma Laboratories, L.P. | 3 | $89 |
| Novartis Pharmaceuticals Corporation | 3 | $88 |
| Janssen Biotech, Inc. | 2 | $37 |
| ABBVIE INC. | 2 | $35 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $34 |
| E.R. Squibb & Sons, L.L.C. | 1 | $14 |
Products named: Otezla, BLU-U, NEMLUVIO, DUPIXENT, COSENTYX, TREMFYA, SKYRIZI, SPEVIGO.
Industry payments across CA — which companies pay providers there.
